Moderna, Inc. (NASDAQ:MRNA) Position Trimmed by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S lowered its stake in Moderna, Inc. (NASDAQ:MRNA) by 40.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,404 shares of the company’s stock after selling 11,058 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Moderna were worth $682,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of MRNA. Allworth Financial LP lifted its holdings in shares of Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after purchasing an additional 281 shares during the last quarter. Howard Capital Management Inc. raised its holdings in Moderna by 3.1% during the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after buying an additional 297 shares during the period. Commonwealth Equity Services LLC lifted its stake in Moderna by 0.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company’s stock valued at $3,099,000 after buying an additional 345 shares in the last quarter. Larson Financial Group LLC boosted its holdings in shares of Moderna by 39.1% in the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company’s stock worth $53,000 after buying an additional 356 shares during the period. Finally, New Insight Wealth Advisors increased its position in shares of Moderna by 4.4% in the fourth quarter. New Insight Wealth Advisors now owns 8,545 shares of the company’s stock worth $355,000 after acquiring an additional 358 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock opened at $26.52 on Thursday. The stock’s 50 day simple moving average is $30.48 and its 200 day simple moving average is $39.07. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $170.47. The company has a market capitalization of $10.25 billion, a price-to-earnings ratio of -2.86 and a beta of 2.23.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Evercore ISI set a $50.00 price objective on shares of Moderna in a research note on Friday, February 14th. Leerink Partners lowered their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Thursday, April 17th. JPMorgan Chase & Co. lowered their target price on Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a research note on Friday, March 21st. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a research report on Tuesday, February 18th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average target price of $58.70.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.